Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters

Database
Document Type
Year range
1.
Revista Alergia Mexico ; 69(1):61-64, 2022.
Article in Spanish | EMBASE | ID: covidwho-1969987

ABSTRACT

Objective: To assess cutaneous reactions after Pfizer-BioNTech COVID-19 vaccine administration. Methods: A cross-sectional observational study was carried out in health workers belonging to the city of Guayaquil-Ecuador, from March to May 2021. The participants were contacted through a local registry established by the Universidad Espíritu Santo. Frequencies and percentages were used to represent the proportions of nominal variables, while the mean and standard deviation were used for continuous data, given a normal sample distribution. Results: Local skin reactions were the most frequent, and included redness, edema, and itching. On the other hand, delayed large local skin reactions (generalized rash and pruritus, angioedema, urticaria, eczema, petechiae) were rare and occurred in less than 1.4% of participants, (95% CI = 0.69-1.00). Finally, we did not find cases of anaphylaxis or other life-threatening reactions requiring urgent attention after vaccination. Conclusions: Our findings suggest that local skin reactions occur in a minority of recipients and are often mild and self-limited.

2.
Allergy: European Journal of Allergy and Clinical Immunology ; 76(SUPPL 110):483-484, 2021.
Article in English | EMBASE | ID: covidwho-1570379

ABSTRACT

Background: Allergic reactions to vaccines are rare, occurring at 1 per 1'000.000 to 30 per 100.000;BNT162b2 vaccine excipients include polyethylene glycol/macrogol (PEG), rarely cause of allergy. Contact sensitivity to PEG is more frequent than anaphylaxis. CDC reported an estimated rate of 11.1 cases of anaphylaxis per million doses administered in patients with a history of allergies. Method: We prospectively assessed the early allergic reactions of Phase 0 COVID-19 vaccination plan in Guayaquil, Ecuador. Participants received two 30-μg doses, administered intramuscularly 21 days apart. Phase 0 included first line health care workers who were healthy or had stable chronic medical conditions. Participants were observed for 30 minutes after vaccination for any acute reactions;we used Brighton scale for anaphylaxis definition criteria. The primary endpoint was to measure any allergic reaction, anaphylaxis and use of medication within 14 days after the receipt of each dose of vaccine;day 1 referred to the vaccination day. Participants reported their symptoms on weekly telephonic follow-up made by the pollsters team. Results: 187 subjects were enrolled, the mean age was 41.11 ± 17.78, 61% were female and 27.3% patients presented with an allergic past history, 15% had allergic rhinitis (Table 1). Allergic symptom onset was 2.2 ± 3.63 minutes compared to 30 minutes of another study. We did not report any anaphylaxis case. On the first day, 5.35% presented an allergic reaction including generalized rash, injection site rash and petechiae. On second dose, 3.7% presented injection site rash, generalized pruritus and petechiae (Figure 1). Conclusion: Our study found a similar prevalence of allergic reaction according to previous reports. The majority of patients, 94.65%, did not report any allergic symptoms after BNT162b2, similar to previous studies (98%). Anaphylaxis with COVID-19 vaccination is extremely rare, we did not find any case similarly to other reports (0.027%). To our knowledge, this is the first study to report acute allergic reactions in South America. Further studies are needed in order to prove the allergic reactions differences with other populations. (Table Presented).

SELECTION OF CITATIONS
SEARCH DETAIL